SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the revised Certificate of Suitability (CEP) for Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM). The main reason for this revision is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will be effective from September 12, 2025

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.